Intrinsic Imaging Awarded Global Clinical Trial for Hepatocellular Carcinomas

Bolton, MA, San Antonio, TX (PRWEB) APRIL 23, 2014 — Intrinsic Imaging, an FDA audited, ISO 9001, ISO 13485 and ISO 22301:2012 certified medical imaging core lab specializing in providing imaging core lab services for clinical trials, announced today that it has been awarded a global clinical trial to assess patients with hepatocellular carcinomas (HCC).

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, protocol and charter development, site qualification, site training and management, image transfer, blinding and processing as well as the specialized radiologic review of images acquired using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI).

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver. According to the American Cancer Society, Hepatocellular carcinoma has become one of the most common types of cancer in many countries with more than 700000 people diagnosed annually worldwide.

The incidence of HCC is highest in Asia and Africa, where the endemic high prevalence of hepatitis B and hepatitis C strongly predisposes to the development of chronic liver disease and subsequent development of hepatocellular carcinoma. Hepatocellular carcinoma has become one of the leading causes of cancer deaths worldwide, accounting for more than 600000 deaths each year.

Intrinsic Imaging's team of more than sixty board-certified diagnostic radiologists has subspecialization in all therapeutic areas including, but not limited to, Oncology, Cardiovascular and Thoracic, Central Nervous System, Gastrointestinal & Genitourinary, Musculoskeletal, and Medical Device. The Intrinsic Oncology team consists of 12 fellowship-trained board-certified radiologists, and 8 board-certified interventional radiologists who have in-depth experience in liver, colorectal, pancreatic, breast, lung, ovarian and prostate cancer, among others.

"Intrinsic Imaging is dedicated to applying our therapeutic and regulatory expertise throughout this clinical trial towards assisting in the development of a new effective therapy to treat patients with hepatocellular carcinomas." said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging.